network member

California

About Network Member

Currently Enrolling

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
MD Anderson Cancer Center
Novant Health Oncology Specialists
Providence Cancer Institute
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
The Ohio State University
UC San Francisco
University of Michigan Rogel Cancer Center
Currently Enrolling

HCRN-BSK22-562

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
Cancer areas:Basket
AdventHealth Orlando
CARTI
John Theurer Cancer Center at Hackensack Meridian Health
Meritus Center for Clinical Research / John R. Marsh Cancer Center
Salinas Valley Health
University of Louisville / James Graham Brown Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

HCRN-GU19-385

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)
Cancer areas:Prostate
City of Hope
Froedtert & the Medical College of Wisconsin
Knight Cancer Institute at Oregon Health & Science University
University of Michigan Rogel Cancer Center
Winship Cancer Institute of Emory University
Currently Enrolling

HCRN-GU20-436

NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
Cancer areas:Prostate
Columbia University Irving Medical Center
Memorial Sloan Kettering Cancer Center
Moores Cancer Center at UC San Diego Health
Penn Medicine Abramson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrollment Closed

HCRN-GU20-444

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing
Cancer areas:Bladder
City of Hope
Icahn School of Medicine at Mount Sinai
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
University of New Mexico Comprehensive Cancer Center
Currently Enrolling

HCRN-GU21-517

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)
Cancer areas:Prostate
Moores Cancer Center at UC San Diego Health
The University of Chicago Medicine Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Columbia University Irving Medical Center
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
John Theurer Cancer Center at Hackensack Meridian Health
Moores Cancer Center at UC San Diego Health
Penn Medicine Abramson Cancer Center
The Ohio State University
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Weill Cornell Medicine
Winship Cancer Institute of Emory University
Yale Cancer Center
Currently Enrolling

HCRN-HN23-623

A Phase II, Single Arm, Open Label, Multi-center Trial of Neoadjuvant Radiation and Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Previously Untreated Locally Advanced, Resectable, HPV Mediated Oropharynx Cancer
Cancer areas:Head and Neck
Moores Cancer Center at UC San Diego Health
Providence Cancer Institute
Currently Enrolling

HCRN-LUN21-534

DURABLE: Delayed or Upfront brain RAdiotherapy in treatment naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and rEarrangements
Cancer areas:Lung
Stanford University
The Ohio State University
Currently Enrolling

HCRN-LYM21-544

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms
Cancer areas:Lymphoma
City of Hope
The Ohio State University
University of Michigan Rogel Cancer Center
Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
University of Alabama at Birmingham Comprehensive Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Enrollment Closed

HCRN-GU16-257

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing
Cancer areas:Bladder
City of Hope
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Knight Cancer Institute at Oregon Health & Science University
Penn Medicine Abramson Cancer Center
University of Wisconsin Carbone Cancer Center
USC Norris Comprehensive Cancer Center
Enrollment Closed

HCRN-MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma
Cancer areas:Melanoma
Columbia University Irving Medical Center
Georgetown Lombardi Comprehensive Cancer Center
MD Anderson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
UC San Francisco
Enrollment Closed

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Cancer areas:Breast
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
UPMC Hillman Cancer Center
Vanderbilt-Ingram Cancer Center